[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598290":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":42,"centralContacts":47,"locations":53,"responsibleParty":217,"collaborators":11,"id":219,"slug":220,"hasResults":221,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":11,"eligibilityCriteria":225,"healthyVolunteers":221,"sex":226,"minAge":227,"maxAge":228,"enrollmentInfo":229,"targetDuration":11,"studyType":232,"phases":233,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":56,"whyStopped":11,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},{"fullName":5,"class":6},"Ausper Biopharma Co., Ltd.","INDUSTRY",[8,15,18,22,25],{"label":9,"type":10,"description":11,"interventionNames":12},"AHB-137 (16 weeks) and Peg-IFN","EXPERIMENTAL",null,[13,14],"Drug: AHB-137","Drug: Peg-IFN",{"label":16,"type":10,"description":11,"interventionNames":17},"AHB-137 (24 weeks) and Peg-IFN",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"AHB-137 and Hepatitis B vaccine",[13,21],"Drug: Hepatitis B Vaccine",{"label":23,"type":10,"description":11,"interventionNames":24},"AHB-137",[13],{"label":26,"type":10,"description":27,"interventionNames":28},"AHB-137 (24 weeks) and Peg-IFN(24 weeks)","R3 group",[13,14],[30,34,38],{"type":31,"name":23,"description":32,"armGroupLabels":33,"otherNames":11},"DRUG","AHB-137 will be injected.",[23,9,16,26,19],{"type":31,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"Peg-IFN","Peg-IFN will be administered .",[9,16,26],{"type":31,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"Hepatitis B Vaccine","Hepatitis B vaccine will be administered.",[19],[43],{"name":44,"affiliation":45,"role":46},"Jia","Beijing Friendship Hospital","PRINCIPAL_INVESTIGATOR",[48],{"name":49,"role":50,"phone":51,"phoneExt":11,"email":52},"Lu","CONTACT","0571-86959519","clinicaltrial@ausperbio.com",[54,72,86,98,110,118,129,137,149,161,173,185,193,205],{"facility":55,"status":56,"city":57,"state":58,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Beijing Friendship Hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":62,"coordinates":63},"Point",[64,65],116.39723,39.9075,{"lat":65,"lon":64},[68],{"name":69,"role":50,"phone":70,"phoneExt":11,"email":71},"Zuo","010-63139003","yyyyecp1@163.com",{"facility":73,"status":56,"city":74,"state":75,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"AusperBio Investigational Site","Chongqing","Chongqing Municipality",{"type":62,"coordinates":77},[78,79],106.55771,29.56026,{"lat":79,"lon":78},[82,84],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},"057186959519",{"name":85,"role":46,"phone":11,"phoneExt":11,"email":11},"Peng Hu",{"facility":73,"status":56,"city":87,"state":88,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Fuzhou","Fujian",{"type":62,"coordinates":90},[91,92],119.30611,26.06139,{"lat":92,"lon":91},[95,96],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":97,"role":46,"phone":11,"phoneExt":11,"email":11},"Haibing Gao",{"facility":73,"status":56,"city":99,"state":100,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Guangzhou","Guangdong",{"type":62,"coordinates":102},[103,104],113.25,23.11667,{"lat":104,"lon":103},[107,108],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":109,"role":46,"phone":11,"phoneExt":11,"email":11},"Bingliang Lin",{"facility":73,"status":56,"city":99,"state":100,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":111,"geoPoint":113,"contacts":114},{"type":62,"coordinates":112},[103,104],{"lat":104,"lon":103},[115,116],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":117,"role":46,"phone":11,"phoneExt":11,"email":11},"Yujuan Guan",{"facility":73,"status":56,"city":119,"state":100,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Shenzhen",{"type":62,"coordinates":121},[122,123],114.0683,22.54554,{"lat":123,"lon":122},[126,127],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":128,"role":46,"phone":11,"phoneExt":11,"email":11},"Hongzhou Lu",{"facility":73,"status":56,"city":119,"state":100,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":130,"geoPoint":132,"contacts":133},{"type":62,"coordinates":131},[122,123],{"lat":123,"lon":122},[134,135],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":136,"role":46,"phone":11,"phoneExt":11,"email":11},"Guoxin Hu",{"facility":73,"status":56,"city":138,"state":139,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Zunyi","Guizhou",{"type":62,"coordinates":141},[142,143],106.90722,27.68667,{"lat":143,"lon":142},[146,147],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":148,"role":46,"phone":11,"phoneExt":11,"email":11},"Yawen Luo",{"facility":73,"status":56,"city":150,"state":151,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Wuhan","Hubei",{"type":62,"coordinates":153},[154,155],114.26667,30.58333,{"lat":155,"lon":154},[158,159],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":160,"role":46,"phone":11,"phoneExt":11,"email":11},"Xin Zheng",{"facility":73,"status":56,"city":162,"state":163,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Changchun","Jilin",{"type":62,"coordinates":165},[166,167],125.32278,43.88,{"lat":167,"lon":166},[170,171],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":172,"role":46,"phone":11,"phoneExt":11,"email":11},"Yanhang Gao",{"facility":73,"status":56,"city":174,"state":175,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Chengdu","Sichuan",{"type":62,"coordinates":177},[178,179],104.06667,30.66667,{"lat":179,"lon":178},[182,183],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":184,"role":46,"phone":11,"phoneExt":11,"email":11},"Jianmei Lin",{"facility":73,"status":56,"city":174,"state":175,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":186,"geoPoint":188,"contacts":189},{"type":62,"coordinates":187},[178,179],{"lat":179,"lon":178},[190,191],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":192,"role":46,"phone":11,"phoneExt":11,"email":11},"Li Zhu",{"facility":73,"status":56,"city":194,"state":195,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"Kunming","Yunnan",{"type":62,"coordinates":197},[198,199],102.71833,25.03889,{"lat":199,"lon":198},[202,203],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":204,"role":46,"phone":11,"phoneExt":11,"email":11},"Jia Wei",{"facility":73,"status":56,"city":206,"state":207,"zip":11,"country":59,"countryCode":60,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"Hangzhou","Zhejiang",{"type":62,"coordinates":209},[210,211],120.16142,30.29365,{"lat":211,"lon":210},[214,215],{"name":49,"role":50,"phone":83,"phoneExt":11,"email":52},{"name":216,"role":46,"phone":11,"phoneExt":11,"email":11},"Fangfang Lv",{"type":218,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100598290","phase-2-a-multicenter-study-of-ahb-137-injection-combined-with-other-hepatitis-b-drugs-100598290",false,"NCT07069569","A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs","A Randomized, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Combination With Hepatitis B Vaccine or Pegylated Interferon α-2b (Peg-IFN) in Participants With HBeAg-Negative Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogue (NAs)","Inclusion Criteria:\n\n* Participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening, able to complete the study according to the protocol;\n* Aged between 18 and 65 years at the time of signing the ICF;\n* Body mass index (BMI) within the range of 18-30 kg\u002F m2;\n* HBeAg negative at screening;\n* HBsAg or HBV DNA positive for at least 6 months;\n* Continue antiviral therapy with a single nucleoside (t) ide analogue for more than 6 months prior to screening;\n* Alanine aminotransferase (ALT) ≤ 2 × upper limit of normal (ULN);\n* Effective contraception as required.\n\nExclusion Criteria:\n\n* Participants who are not eligible for treatment with Peg-IFN\u002Frecombinant hepatitis B vaccine;\n* Clinically significant abnormalities other than a history of chronic HBV infection;\n* Concomitant clinically significant other liver diseases;\n* Any serious infection other than chronic hepatitis B infection requiring intravenous anti-infective therapy within 1 month prior to screening;\n* HCV RNA positive, Human immunodeficiency virus (HIV) positive, syphilis positive;\n* Significant liver fibrosis or cirrhosis at screening, or a liver stiffness value (LSM) \\> 9.0 kPa;\n* Previous\u002Fcurrent manifestations of hepatic decompensation;\n* Diagnosis or suspicion of hepatocellular carcinoma, or alpha-fetoprotein concentration (AFP) ≥ 20 ng\u002FmL at screening;\n* Obviously abnormal laboratory test results;\n* History of vasculitis or presence of signs, symptoms, or laboratory tests of underlying vasculitis, and previous\u002Fcurrent other diseases that may be related to vasculitic conditions;\n* QT interval corrected for heart rate (Fridericia method) abnormal;\n* History of extrahepatic disease possibly related to HBV immune status;\n* Participants with a history of malignancy within the past 5 years or who are being evaluated for a possible malignancy;\n* Serious mental illness or history of serious mental illness prior to screening;\n* Suspected history of allergy to any component of the study drug, or allergic constitution;\n* Major trauma or major surgery within 3 months prior to screening, or planned surgery during the study;\n* Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;\n* Current use or use of any immunosuppressive medication within 3 months prior to screening, with the exception of short courses (≤ 2 weeks) or use of topical\u002Finhaled steroids;Those who have used immunomodulators and cytotoxic drugs within 6 months prior to the first dose;Or a history of vaccination within 6 months prior to screening or a live vaccination plan during the trial;\n* Participants requiring regular long-term administration of anticoagulants or antiplatelet drugs;\n* Thyroid dysfunction;\n* Patients with uncontrolled epilepsy and other progressive neurological disorders;\n* Received any antisense oligonucleotides (ASO) or small molecule interfering ribonucleic acid (siRNA) drug;\n* Any other circumstance or condition that, in the opinion of the investigator, the participants are inappropriate for participation in the study.","ALL","18 Years","65 Years",{"count":230,"type":231},200,"ESTIMATED","INTERVENTIONAL",[234],"PHASE2","This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.",[237],"Chronic Hepatitis B",[239],"Hepatitis B, Chronic","2026-07-28",{"date":242,"type":243},"2026-07-29","ACTUAL",{"date":245,"type":243},"2025-06-08",{"date":247,"type":231},"2028-01-15",{"name":5,"class":6},14]